HK Stock Market Move | XUNCE Technology (03317) rises more than 26%, shareholders approve share buyback plan, and recently receives positive outlook from multiple securities firms.
Xunji Technology (03317) surged over 26%, as of the time of release, it rose 21.65%, to 125.3 Hong Kong dollars, with a trading volume of 325 million Hong Kong dollars.
XUNCE Technology (03317) surged more than 26%, rising by 21.65% to HK$125.3 as of the time of publication, with a turnover of HK$325 million.
On the news front, on the evening of June 26, XUNCE Technology announced that the company held its 2025 annual general meeting of shareholders on the same day, deliberating and passing all 12 ordinary and special resolutions, including the "Authorization for the Board to Repurchase Shares" which has drawn attention from the market. According to this authorization, the Board is granted the approval to repurchase up to 10% of the total number of H shares issued by the company on the day of the resolution. Based on the total number of H shares issued by the company as of the last feasible date of 267,175,506 shares, this authorization allows for the repurchase of up to approximately 26.718 million H shares.
It is worth noting that since June 2026, XUNCE Technology has received positive outlooks from several major brokerage firms such as HAITONG INT'L, CITIC SEC, Huatai, China Securities Co., Ltd. China Securities Co., Ltd. believes that XUNCE has established three major core barriers: the ability to process real-time data throughout the entire chain in milliseconds, over a decade of unreplicable Know-how in high-barrier industries, and a retention rate of over 90% from embedding products deep into customer processes. Huatai pointed out that the company's TokenOS covers data cleaning, modeling, real-time calculation, model adaptation throughout the entire chain, and outputs standardized Tokens that can directly drive business decisions, suitable for high-premium tracks such as healthcare, energy, and high-end manufacturing.
Related Articles

UBS: Maintain target price of HK$8.9 for CHINA GAS HOLD (00384) with a "Buy" rating.

HK Stock Market Move | Simcere Pharma (02096) rose nearly 9% in the morning. Recently, it reached a research cooperation agreement with the Stanford University School of Medicine to develop innovative therapies for IPF patients.

HK Stock Market Move | PEIJIA-B(09996) rose more than 10%, innovative products in large volume are expected to help accelerate the company's performance growth.
UBS: Maintain target price of HK$8.9 for CHINA GAS HOLD (00384) with a "Buy" rating.

HK Stock Market Move | Simcere Pharma (02096) rose nearly 9% in the morning. Recently, it reached a research cooperation agreement with the Stanford University School of Medicine to develop innovative therapies for IPF patients.

HK Stock Market Move | PEIJIA-B(09996) rose more than 10%, innovative products in large volume are expected to help accelerate the company's performance growth.

RECOMMEND





